Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology - PubMed (original) (raw)
Review
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
Cem Akin. J Mol Diagn. 2006 Sep.
Abstract
Mastocytosis is a disease characterized by pathological mast cell accumulation and activation in tissues. Most patients with mastocytosis exhibit the D816V point mutation in the tyrosine kinase domain of the transmembrane receptor protein Kit, leading to its constitutive activation in bone marrow or lesional skin tissue. Detection of a codon 816 c-kit mutation is included as a minor diagnostic criterion in the World Health Organization's diagnostic criteria for systemic mastocytosis. Determining mutational status of the c-kit gene also has pharmacogenomic implications in patients considered for investigational mast cell cytoreductive therapies. This article reviews diagnostic and therapeutic implications of c-kit mutations as well as other less common molecular abnormalities observed in mast cell disease.
Figures
Figure 1
Multifocal clusters of mast cells in a bone marrow biopsy visualized by immunohistochemical staining for tryptase satisfy the World Health Organization major diagnostic criterion in this patient with indolent systemic mastocytosis.
Figure 2
Mast cells in bone marrow aspirate smears show aberrant morphological features such as spindling and hypogranulation (A), as compared to normal mast cells with a round and centrally located nucleus and dense cytoplasmic granulation (B).
Figure 3
C-_kit_mutations in mastocytosis. EC, extracellular (ligand binding); TM, transmembrane; JM, juxtamembrane; TK, tyrosine kinase domain. The most common mutation, D816V, is shown boxed.
Figure 4
Demonstration of D816V c-_kit_mutation by RFLP (A) and capillary sequencing (B). A:_Hin_fI digestion of the RT-PCR product from HMC1.2 cell line (lane 1, positive control) and patient samples in lanes 4 and 6 show the presence of an additional band (arrow) as a result of creating a new restriction site by A>T nucleotide change in c-_kit_codon 816. Lanes 2, 3, and 5 show wild-type pattern codon 816. B: Demonstration of the heterozygous A>T nucleotide change in cDNA position 2468 (corresponding to amino acid change D816V) by direct capillary sequencing (right), and its comparison to the wild-type sequence (left).
Similar articles
- Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG, Metcalfe DD. Taylor ML, et al. J Mol Diagn. 2004 Nov;6(4):335-42. doi: 10.1016/S1525-1578(10)60529-6. J Mol Diagn. 2004. PMID: 15507672 Free PMC article. - Mastocytosis: state of the art.
Horny HP, Sotlar K, Valent P. Horny HP, et al. Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711. Pathobiology. 2007. PMID: 17587883 Review. - [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K. Sotlar K. Verh Dtsch Ges Pathol. 2007;91:169-76. Verh Dtsch Ges Pathol. 2007. PMID: 18314612 German. - Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I. Longley BJ, et al. Nat Genet. 1996 Mar;12(3):312-4. doi: 10.1038/ng0396-312. Nat Genet. 1996. PMID: 8589724 - Mastocytosis.
Metcalfe DD. Metcalfe DD. Novartis Found Symp. 2005;271:232-42; discussion 242-9. Novartis Found Symp. 2005. PMID: 16605139 Review.
Cited by
- Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib.
Saheb Kashaf S, Godley LA, Chadha A, Waldinger JB. Saheb Kashaf S, et al. JAAD Case Rep. 2023 Apr 24;37:119-122. doi: 10.1016/j.jdcr.2023.04.007. eCollection 2023 Jul. JAAD Case Rep. 2023. PMID: 37405177 Free PMC article. No abstract available. - Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S, Chifotides HT, Khoury JD, Verstovsek S, Thakral B. El Hussein S, et al. Cancers (Basel). 2022 Jul 17;14(14):3474. doi: 10.3390/cancers14143474. Cancers (Basel). 2022. PMID: 35884535 Free PMC article. Review. - Efficacy of Omalizumab in Indolent Systemic Mastocytosis.
Slapnicar C, Trinkaus M, Hicks L, Vadas P. Slapnicar C, et al. Case Rep Hematol. 2019 Sep 16;2019:3787586. doi: 10.1155/2019/3787586. eCollection 2019. Case Rep Hematol. 2019. PMID: 31637065 Free PMC article. - Impact of somatic and germline mutations on the outcome of systemic mastocytosis.
Muñoz-González JI, Jara-Acevedo M, Alvarez-Twose I, Merker JD, Teodosio C, Hou Y, Henriques A, Roskin KM, Sanchez-Muñoz L, Tsai AG, Caldas C, Matito A, Sánchez-Gallego JI, Mayado A, Dasilva-Freire N, Gotlib JR, Escribano L, Orfao A, García-Montero AC. Muñoz-González JI, et al. Blood Adv. 2018 Nov 13;2(21):2814-2828. doi: 10.1182/bloodadvances.2018020628. Blood Adv. 2018. PMID: 30373888 Free PMC article. - Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions.
Böhm R, Cascorbi I. Böhm R, et al. Front Pharmacol. 2016 Oct 21;7:396. doi: 10.3389/fphar.2016.00396. eCollection 2016. Front Pharmacol. 2016. PMID: 27818635 Free PMC article. Review.
References
- Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419–432. - PubMed
- Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–690. - PubMed
- Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519–528. - PubMed
- Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:695–717. - PubMed
- Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62:965–972. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources